Patents by Inventor Jonathan Sjogren

Jonathan Sjogren has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Treatment for IgE-mediated disease
    Patent number: 9707279
    Abstract: The invention provides an EndoS polypeptide, or a polynucleotide encoding an EndoS polypeptide, for use in a method for treating or preventing a disease or condition mediated by IgE antibodies.
    Type: Grant
    Filed: March 5, 2012
    Date of Patent: July 18, 2017
    Assignee: Hansa Medical AB
    Inventors: Mattias Collin, Rolf Lood, Karl Carlstrom, Maria Allhorn, Jonathan Sjogren, Falk Nimmerjahn
  • Endoglycosidase from and methods using it
    Patent number: 9493752
    Abstract: The invention provides an endoglycosidase, referred to as EndoS49 and having the amino acid sequence of SEQ ID NO: 1. EndoS49 was isolated from Streptococcus pyogenes strain NZ131 and is a homolog of EndoS. EndoS49 has specific endoglycosidase activity on native IgG and cleaves a larger variety of Fc glycans than EndoS. A mutant thereof where the glutamic acid at position 186 of SEQ ID NO: 1 was substituted was produced: said mutant lacks endoglycosidase activity but is capable of binding to IgG. Methods using EndoS49, deletions thereof and said mutant, especially for assessing glycosylation of IgG or for isolating IgG are disclosed.
    Type: Grant
    Filed: September 12, 2012
    Date of Patent: November 15, 2016
    Assignee: Genovis AB
    Inventors: Mattias Collin, Maria Allhorn, Jonathan Sjögren
  • ENDOGLYCOSIDASE FROM STREPTOCOCCUS PYOGENES AND METHODS USING IT
    Publication number: 20140302519
    Abstract: The invention provides an endoglycosidase, referred to as EndoS49 and having the amino acid sequence of SEQ ID NO: 1. EndoS49 was isolated from Streptococcus pyogenes strain NZ131 and is a homolog of EndoS. EndoS49 has specific endoglycosidase activity on native IgG and cleaves a larger variety of Fc glycans than EndoS. A mutant thereof where the glutamic acid at position 186 of SEQ ID NO: 1 was substituted was produced: said mutant lacks endoalvcosidase activity but is capable of binding to IgG. Methods using EndoS49, deletions thereof and said mutant, especially for assessing glycosylation of IgG or for isolating IgG are disclosed.
    Type: Application
    Filed: September 12, 2012
    Publication date: October 9, 2014
    Applicant: Genovis AB
    Inventors: Mattias Collin, Maria Allhorn, Jonathan Sjögren
  • TREATMENT FOR IgE-MEDIATED DISEASE
    Publication number: 20140065128
    Abstract: The invention provides an EndoS polypeptide, or a polynucleotide encoding an EndoS polypeptide, for use in a method for treating or preventing a disease or condition mediated by IgE antibodies.
    Type: Application
    Filed: March 5, 2012
    Publication date: March 6, 2014
    Applicant: HANSA MEDICAL AB
    Inventors: Mattias Collin, Rolf Lood, Karl Carlstrom, Maria Allhorn, Jonathan Sjogren, Falk Nimmerjahn